S&P 500   5,100.95
DOW   38,959.26
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,100.95
DOW   38,959.26
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,100.95
DOW   38,959.26
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,100.95
DOW   38,959.26
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
China's manufacturing activity contracts for 5th straight month despite policy support

Ovid Therapeutics (OVID) Competitors

$3.40
-0.03 (-0.87%)
(As of 02/29/2024 ET)

OVID vs. RPTX, XOMA, ENTA, SBTX, VNDA, HOWL, ZVRA, ANNX, FHTX, and NLTX

Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Repare Therapeutics (RPTX), XOMA (XOMA), Enanta Pharmaceuticals (ENTA), Silverback Therapeutics (SBTX), Vanda Pharmaceuticals (VNDA), Werewolf Therapeutics (HOWL), Zevra Therapeutics (ZVRA), Annexon (ANNX), Foghorn Therapeutics (FHTX), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.

Ovid Therapeutics vs.

Repare Therapeutics (NASDAQ:RPTX) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Ovid Therapeutics received 308 more outperform votes than Repare Therapeutics when rated by MarketBeat users. Likewise, 70.45% of users gave Ovid Therapeutics an outperform vote while only 60.00% of users gave Repare Therapeutics an outperform vote.

CompanyUnderperformOutperform
Repare TherapeuticsOutperform Votes
33
60.00%
Underperform Votes
22
40.00%
Ovid TherapeuticsOutperform Votes
341
70.45%
Underperform Votes
143
29.55%

Repare Therapeutics presently has a consensus price target of $17.33, indicating a potential upside of 149.40%. Ovid Therapeutics has a consensus price target of $7.17, indicating a potential upside of 110.78%. Given Ovid Therapeutics' higher probable upside, analysts plainly believe Repare Therapeutics is more favorable than Ovid Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repare Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ovid Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Repare Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Repare Therapeutics has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repare Therapeutics$131.83M2.22-$29.05M-$2.31-3.01
Ovid Therapeutics$1.50M160.21-$54.17M-$0.69-4.93

Repare Therapeutics has a net margin of -173.09% compared to Repare Therapeutics' net margin of -16,392.23%. Ovid Therapeutics' return on equity of -38.60% beat Repare Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Repare Therapeutics-173.09% -38.60% -30.25%
Ovid Therapeutics -16,392.23%-41.72%-34.67%

In the previous week, Repare Therapeutics had 7 more articles in the media than Ovid Therapeutics. MarketBeat recorded 9 mentions for Repare Therapeutics and 2 mentions for Ovid Therapeutics. Repare Therapeutics' average media sentiment score of 0.49 beat Ovid Therapeutics' score of 0.12 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Repare Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ovid Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

85.1% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Ovid Therapeutics shares are owned by institutional investors. 28.5% of Repare Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Repare Therapeutics beats Ovid Therapeutics on 11 of the 17 factors compared between the two stocks.


Get Ovid Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OVID vs. The Competition

MetricOvid TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$240.31M$6.73B$4.89B$7.51B
Dividend YieldN/A2.80%2.87%3.86%
P/E Ratio-4.9314.61273.8718.26
Price / Sales160.211,196.413,453.79305.48
Price / CashN/A19.5294.5454.73
Price / Book1.814.824.464.54
Net Income-$54.17M$161.15M$114.20M$211.48M
7 Day Performance-8.11%5.10%4.27%2.63%
1 Month Performance-12.14%11.83%8.77%5.46%
1 Year Performance36.00%5.15%12.06%8.67%

Ovid Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RPTX
Repare Therapeutics
3.3143 of 5 stars
$6.28
-5.3%
$16.50
+162.7%
-32.2%$264.58M$131.83M-2.72180Short Interest ↓
XOMA
XOMA
4.1067 of 5 stars
$22.28
-3.7%
$74.00
+232.1%
+14.2%$256.00M$6.03M-7.9312
ENTA
Enanta Pharmaceuticals
4.1564 of 5 stars
$12.79
-1.5%
$19.33
+51.2%
-70.4%$270.64M$79.20M-1.95145Short Interest ↑
SBTX
Silverback Therapeutics
0 of 5 stars
$7.52
+4.9%
N/A+6.1%$271.16MN/A-3.1183Gap Down
High Trading Volume
VNDA
Vanda Pharmaceuticals
2.5634 of 5 stars
$4.35
-0.7%
N/A-30.6%$252.01M$192.64M87.02203Analyst Downgrade
Short Interest ↑
HOWL
Werewolf Therapeutics
2.7018 of 5 stars
$6.76
-1.9%
$10.58
+56.4%
+139.9%$274.86M$16.40M-6.1546Short Interest ↑
ZVRA
Zevra Therapeutics
1.2667 of 5 stars
$6.89
+0.4%
$18.00
+161.2%
N/A$249.56M$10.46M-5.9932Upcoming Earnings
ANNX
Annexon
3.3925 of 5 stars
$5.19
+1.2%
$13.14
+153.2%
+4.5%$276.32MN/A-2.7376Upcoming Earnings
Analyst Upgrade
Short Interest ↓
Gap Up
High Trading Volume
FHTX
Foghorn Therapeutics
1.7966 of 5 stars
$5.91
-9.4%
$14.83
+151.0%
+34.9%$249.52M$19.23M-2.40161Short Interest ↑
Gap Up
NLTX
Neoleukin Therapeutics
0 of 5 stars
$29.46
-1.8%
$30.00
+1.8%
+204.9%$276.87MN/A-9.477

Related Companies and Tools

This page (NASDAQ:OVID) was last updated on 3/1/2024 by MarketBeat.com Staff